The main purpose of this study is to investigate primary cervical dystonia as compared to
healthy control subjects and DYT 1 dystonia as compared to healthy control subjects by
examining cognitive measures, physical measures, and structural and functional magnetic
resonance imaging (MRI).
The secondary aim of this study is to investigate a specific drug therapy for primary
cervical dystonia to develop a functional MRI (fMRI) research paradigm. The drug,
trihexyphenidyl, is FDA approved to treat Parkinson's Disease and is commonly prescribed by
physicians as a treatment for symptoms of primary cervical dystonia.
Details
Lead Sponsor:
University of Florida
Collaborator:
Bachmann Strauss Dystonia & Parkinson Foundation, Inc.